MICHAEL E. CASTAGNA, PHARM.D. - Corporate Board Profile

MANNKIND CORP

Filing Date	Source Excerpt
2018-03-29	Michael E. Castagna, Pharm.D. has served as our Chief Executive Officer and as one of our directors since May 2017. Mr. Castagna also served as a Corporate Vice President, Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined the Company, Mr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen's Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb Co. Before BMS, Mr. Castagna served as Vice President & Head, Biopharmaceuticals, North America, at Sandoz. He has also held positions with commercial responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from University of the Sciences-Philadelphia College of Pharmacy, a Doctor of Pharmacy from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. The Board believes that Mr. Castagna's knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors. Summary Compensation Table Michael E. Castagna, Pharm.D. Chief Executive Officer 2017 Total($) 1,333,234
2019-03-28	Michael E. Castagna, Pharm.D. has served as our Chief Executive Officer and as one of our directors since May 2017. ... The Board believes that Dr. Castagna's knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
2020-04-10	Michael E. Castagna, Pharm.D. has served as our Chief Executive Officer and as one of our directors since May 2017. ... The Board believes that Mr. Castagna's knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
2021-04-07	Michael E. Castagna, Pharm.D. has served as our Chief Executive Officer and as one of our directors since May 2017. ... Mr. Castagna was determined not to be independent under applicable Nasdaq listing standards due to his position as an executive officer of our company.
2022-03-30	MICHAEL E. CASTAGNA, PHARM.D. Director Chief Executive Officer Age: 45 Director since: 2017 The Board believes that Mr. Castagna’s knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualify him to serve on our Board of Directors. Mr. Castagna has served as our Chief Executive Officer and as one of our directors since May 2017.
2023-04-10	MICHAEL E. CASTAGNA, PHARM.D. Director Chief Executive Officer Age: 46 Director since: 2017
2024-04-05	MICHAEL E. CASTAGNA, PHARM.D. Director Chief Executive Officer Age: 47 Director since: 2017 The Board believes that Dr. Castagna’s knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualify him to serve on our Board of Directors. Michael E. Castagna, Pharm.D. has served as our Chief Executive Officer and as one of our directors since May 2017 and was our Chief Commercial Officer from March 2016 until May 2017.
2025-04-01	MICHAEL E. CASTAGNA, PHARM.D. Director Chief Executive Officer Age: 48 Director since: 2017 ... Michael E. Castagna has served as our Chief Executive Officer and as one of our directors since May 2017 ... Summary Compensation Table ... Michael E. Castagna total compensation for 2024 was $9,490,628.